Form 8-K - Current report:
SEC Accession No. 0001213900-24-089108
Filing Date
2024-10-21
Accepted
2024-10-21 09:15:20
Documents
15
Period of Report
2024-10-21
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea021808801-8k_cero.htm   iXBRL 8-K 29430
2 PRESS RELEASE, DATED OCTOBER 21, 2024 ea021808801ex99-1_cero.htm EX-99.1 12502
  Complete submission text file 0001213900-24-089108.txt   270428

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cero-20241021.xsd EX-101.SCH 3798
4 XBRL DEFINITION FILE cero-20241021_def.xml EX-101.DEF 27115
5 XBRL LABEL FILE cero-20241021_lab.xml EX-101.LAB 37493
6 XBRL PRESENTATION FILE cero-20241021_pre.xml EX-101.PRE 25736
17 EXTRACTED XBRL INSTANCE DOCUMENT ea021808801-8k_cero_htm.xml XML 6106
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 241382135
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)